|
WO2015157636A1
(en)
|
2014-04-10 |
2015-10-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
US10973894B2
(en)
|
2014-10-02 |
2021-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
|
|
EP3075389A1
(en)
*
|
2015-03-31 |
2016-10-05 |
Technische Universität München |
T cell receptors and peptides derived by mutations for the treatment of cancer
|
|
US10544392B2
(en)
|
2015-05-01 |
2020-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017048614A1
(en)
|
2015-09-15 |
2017-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
|
|
CN109843921B
(zh)
|
2016-07-07 |
2023-05-26 |
艾欧凡斯生物治疗公司 |
程序性死亡1配体1(pd-l1)结合蛋白及其应用方法
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
MX2019004707A
(es)
|
2016-10-26 |
2019-08-12 |
Iovance Biotherapeutics Inc |
Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
US11401507B2
(en)
|
2016-11-17 |
2022-08-02 |
Iovance Biotherapeutics, Inc. |
Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
|
|
CA3049165A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
US11254913B1
(en)
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
JOP20190224A1
(ar)
*
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
WO2018183485A1
(en)
*
|
2017-03-31 |
2018-10-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating neoantigen-specific t cell receptor sequences
|
|
BR112019024556A2
(pt)
|
2017-05-24 |
2020-06-23 |
Novartis Ag |
Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
|
|
EP3635097A1
(en)
*
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
EP3684799A1
(en)
|
2017-09-20 |
2020-07-29 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Hla class ii restricted t cell receptors against mutated ras
|
|
EA202090757A1
(ru)
*
|
2017-09-29 |
2020-08-21 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
|
|
CA3080274A1
(en)
*
|
2017-09-29 |
2019-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
|
|
EP3691662A4
(en)
*
|
2017-10-06 |
2021-05-12 |
The University of Chicago |
SCREENING OF T LYMPHOCYTE FOR CANCER SPECIFIC ANTIGENS
|
|
EP4501408A3
(en)
*
|
2017-11-17 |
2025-04-09 |
Iovance Biotherapeutics, Inc. |
Til expansion from fine needle aspirates and small biopsies
|
|
US12221627B2
(en)
|
2017-12-04 |
2025-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells
|
|
EP3724885A2
(en)
*
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
SG11202006541UA
(en)
|
2018-01-08 |
2020-08-28 |
Iovance Biotherapeutics Inc |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
US12415845B2
(en)
|
2018-04-24 |
2025-09-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
|
|
US20210130779A1
(en)
|
2018-04-27 |
2021-05-06 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
*
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CN110857319B
(zh)
*
|
2018-08-24 |
2023-12-08 |
杭州康万达医药科技有限公司 |
一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用
|
|
CN109136281A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种mrfft1细胞的构建方法
|
|
CN110093316A
(zh)
*
|
2018-09-30 |
2019-08-06 |
北京鼎成肽源生物技术有限公司 |
一种aff细胞的构建方法
|
|
CN109136183A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种rff2细胞的构建方法
|
|
CN109294998B
(zh)
*
|
2018-09-30 |
2020-11-06 |
北京鼎成肽源生物技术有限公司 |
一种rff1细胞
|
|
CN109136284B
(zh)
*
|
2018-09-30 |
2020-12-29 |
北京鼎成肽源生物技术有限公司 |
一种afft2细胞
|
|
CN109136277A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrfft2细胞的构建方法
|
|
CN109294983A
(zh)
*
|
2018-09-30 |
2019-02-01 |
北京鼎成肽源生物技术有限公司 |
一种lff2细胞
|
|
CN109136269A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种aff细胞
|
|
CN110093373B
(zh)
*
|
2018-09-30 |
2021-05-07 |
北京鼎成肽源生物技术有限公司 |
一种afft2细胞的构建方法
|
|
CN109295097B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种mrfft2细胞
|
|
CN109679917B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种lrfft2细胞
|
|
CN109294997B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种lrfft1细胞
|
|
CN109136278B
(zh)
*
|
2018-09-30 |
2020-09-29 |
北京鼎成肽源生物技术有限公司 |
一种mrfft1细胞
|
|
CN109136280A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrfft1细胞的构建方法
|
|
CN109294982B
(zh)
*
|
2018-09-30 |
2020-11-06 |
北京鼎成肽源生物技术有限公司 |
一种rff2细胞
|
|
CN109136279A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种mrfft2细胞的构建方法
|
|
CN109136268A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrff细胞的构建方法
|
|
CN110093317A
(zh)
*
|
2018-09-30 |
2019-08-06 |
北京鼎成肽源生物技术有限公司 |
一种lff2细胞的构建方法
|
|
TW202039830A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
|
|
US20220135944A1
(en)
|
2019-02-19 |
2022-05-05 |
Myst Therapeutics, Llc |
Methods for producing autologous t cells useful to treat cancers and compositions thereof
|
|
JP7748284B2
(ja)
*
|
2019-03-04 |
2025-10-02 |
ユニバーシティー ヘルス ネットワーク |
Ｔ細胞受容体及びその使用方法
|
|
CN111748029B
(zh)
*
|
2019-03-29 |
2022-12-13 |
苏州蓝马医疗技术有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111748028A
(zh)
*
|
2019-03-29 |
2020-10-09 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111748027A
(zh)
*
|
2019-03-29 |
2020-10-09 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111848782A
(zh)
*
|
2019-04-25 |
2020-10-30 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CA3145196A1
(en)
*
|
2019-06-24 |
2020-12-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
|
|
WO2021026290A1
(en)
|
2019-08-07 |
2021-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cells having enhanced anti-tumor activity
|
|
CA3162703A1
(en)
|
2019-11-27 |
2021-06-03 |
Myst Therapeutics, Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
CN111019959B
(zh)
*
|
2019-12-30 |
2022-09-13 |
北京立康生命科技有限公司 |
一种体外转录mRNA的核苷酸分子、呈递细胞及应用
|
|
JP7817937B2
(ja)
|
2020-02-27 |
2026-02-19 |
ターンストーン バイオロジクス コーポレイション |
腫瘍反応性ｔ細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物
|
|
CA3171559A1
(en)
|
2020-03-20 |
2021-09-23 |
Sri Krishna |
Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy
|
|
AU2021239379A1
(en)
|
2020-03-20 |
2022-10-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T-cell receptors from peripheral blood by single-cell analysis for immunotherapy
|
|
US12159700B2
(en)
|
2020-04-22 |
2024-12-03 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
US12365871B2
(en)
|
2020-04-28 |
2025-07-22 |
Lyell Immunopharma, Inc. |
Methods for culturing cells
|
|
CN112133372B
(zh)
*
|
2020-08-18 |
2022-06-03 |
北京臻知医学科技有限责任公司 |
抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法
|
|
WO2022055946A1
(en)
|
2020-09-08 |
2022-03-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022086185A1
(ko)
*
|
2020-10-20 |
2022-04-28 |
연세대학교 산학협력단 |
단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
|
|
AU2022246174A1
(en)
|
2021-03-25 |
2023-09-14 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
JP2025537148A
(ja)
*
|
2022-11-04 |
2025-11-14 |
ターンストーン バイオロジクス コーポレイション |
ネオ抗原反応性腫瘍浸潤リンパ球を生成するための組成物および方法
|
|
WO2025080865A1
(en)
|
2023-10-11 |
2025-04-17 |
Turnstone Biologics Corp. |
Combination of tumor infiltrating lymphocytes (til) and low dose radiation
|